TP53 Mutational Status Is a Potential Marker for Risk Stratification in Wilms Tumour with Diffuse Anaplasia

• Mariana Maschietto ,

  Contributed equally to this work with: Mariana Maschietto, Richard D. Williams

  Affiliation Cancer Section, Institute of Child Health, University College London, London, United Kingdom

  ⨯
• Richard D. Williams ,

  Contributed equally to this work with: Mariana Maschietto, Richard D. Williams

  Affiliation Cancer Section, Institute of Child Health, University College London, London, United Kingdom

  ⨯
• Tasnim Chagtai,

  Affiliation Cancer Section, Institute of Child Health, University College London, London, United Kingdom

  ⨯
• Sergey D. Popov,

  Affiliation Divisions of Molecular Pathology and Cancer Therapeutics, Institute of Cancer Research, London, United Kingdom

  ⨯
• Neil J. Sebire,

  Affiliation Departments of Histopathology, Great Ormond Street Hospital, London, United Kingdom

  ⨯
• Gordan Vujanic,

  Affiliation Department of Pathology, School of Medicine, Cardiff University, Cardiff, United Kingdom

  ⨯
• Elizabeth Perlman,

  Affiliation Department of Pathology, Ann and Robert H. Lurie Children's Hospital, Chicago, Illinois, United States of America

  ⨯
• James R. Anderson,

  Affiliation Department of Biostatistics, College of Public Health, University of Nebraska Medical Center, Omaha, Nebraska, United States of America

  ⨯
• Paul Grundy,

  Affiliation Departments of Pediatrics and of Oncology, University of Alberta, Edmonton, Alberta, Canada

  ⨯
• Jeffrey S. Dome,

  Affiliation Division of Pediatric Hematology/Oncology, Children's National Medical Center, Washington, District of Columbia, United States of America

  ⨯
• Kathy Pritchard-Jones

  * E-mail: k.pritchard-jones@ucl.ac.uk

  Affiliation Cancer Section, Institute of Child Health, University College London, London, United Kingdom

  ⨯